

ENRIQUE M. SALDARRIAGA, PhD

Economist & Evidence-to-Decision Leader

+1 206 573 3133 | em.saldarriaga@gmail.com | linkedin.com/in/emsaldarriaga | Arlington, VA

Professional Profile

Economist and decision scientist working at the intersection of evidence generation, resource allocation, and decision-making. My research focuses on two questions: How should scarce resources be allocated across competing priorities, and what do the people and institutions affected by those decisions value? I address these questions using economic evaluation, mathematical and statistical modeling, real-world evidence, preference research, and evidence synthesis. I lead interdisciplinary research groups to translate complex evidence into practical guidance for investment, adoption, implementation, and prioritization decisions. My work has informed national policy and implementation decisions across the United States and Latin America

Education

2022	PhD in Health Economics. The CHOICE Institute. University of Washington, USA <u>Dissertation:</u> The Value of using local data to allocate resources to fight the HIV Epidemic. Case of study in Atlanta, Georgia <u>Reading committee:</u> Anirban Basu (Chair), Ruanne Barnabas, Marita Zimmermann.
2015	Master of Science in Epidemiology. University of Cayetano Heredia, Perú <u>Thesis:</u> Income elasticity of the Body Mass Index in presence of Economic Wealth as effect modifier
2011	Bachelor of Science in Economics. University of the Pacific, Perú <u>Thesis:</u> Cost-benefit analysis of enhancing the Primary Health Care in Peru

Honors

2025	CDC's Director Award for Collaboration in Modeling and Economics, CDC
2022	Schoolwide Outstanding Dissertation Award. School of Pharmacy, University of Washington
2022	3 Minute Thesis Competition Grand Prize Winner. University of Washington
2021	Lusted Award Winner for Outstanding Presentation in Quantitative Methods and Theoretical Developments, 43rd Annual Meeting of the Society for Medical Decision Making
2021	2021 Louis Sr. and Marilyn Garrison Endowed Prize in Health Policy and Economics. The CHOICE Institute, University of Washington
2021	Rubenstein Endowment Grant to support Dissertation research. School of Pharmacy, University of Washington
2019	Lusted Award Finalist for Outstanding Presentation in Health Services, Outcomes, and Policy Research, 41st Annual Meeting of the Society for Medical Decision Making
2018	Stergachis Endowed Fellowship for International Exchange Award. Department of Global Health, University of Washington
2015	Full-Tuition Scholarship to pursue a Master of Science in Epidemiology granted by the School of Public Health and Administration, University Cayetano Heredia.

Publications

Health
Economics

Peer-reviewed (numbered items): 31 total, 13 as first author. [PubMed](#)
Under review (bulleted items): 7 total.
370+ citations (Google Scholar, September 2026)

1. **Saldarriaga EM**, Pollock ED, Jackson DA, et al. *Cost Effectiveness of the Reverse Sequence Algorithm Compared With the Traditional Algorithm for Syphilis Screening Among Pregnant Women*. *Obstet Gynecol* 2025; published online Aug 7.
DOI:10.1097/AOG.0000000000006019.
2. Martin EG, Myderrizi A, Kim H, Gift TL, Hutchinson AB, **Saldarriaga EM**, Chesson HW. *Economic Outcomes of Disease Intervention Specialist-Delivered Interventions for Sexually Transmitted Infections: A Systematic Review*. *Sex Transm Dis* 2025.
<https://doi.org/10.1097/OLQ.0000000000002160>.
3. **Saldarriaga EM**, Beima-Sofie K, Wamalwa D, Mugo C, Njuguna I, Onyango A, et al. *Estimating the costs of adolescent HIV care visits and an intervention to facilitate transition to adult care in Kenya*. *PLoS One*. 2024;19(2):e0296734.
4. Ulrich AK, Adamson BJ, **Saldarriaga EM**, Grecca RDL, Wood D, Babigumira JB, et al. *Finding and treating early-stage HIV infections: A cost-effectiveness analysis of the Sabes study in Lima, Peru*. *Lancet Reg Health Am*. 2022 Aug;12:100281.
5. Shin MB, Garcia PJ, **Saldarriaga EM**, Fiestas JL, Ásbjörnsdóttir KH, Iribarren SJ, et al. *Cost of community-based human papillomavirus self-sampling in Peru: A micro-costing study*. *Lancet Reg Health Am*. 2022 Apr;8:100160.
6. **Saldarriaga EM**, Cárcamo CP, Babigumira JB, García PJ. *The Annual costs of treating genital warts in the Public Healthcare Sector in Peru*. *BMC Health Serv Res*. 2021 Oct 14;21(1):1092.
7. **Saldarriaga EM**, Bravo-Zúñiga J, Hurtado-Roca Y, Suarez V. *Cost-effectiveness analysis of a strategy to delay progression to dialysis and death among chronic kidney disease patients in Lima, Peru*. *Cost Eff Resour Alloc*. 2021 Oct 10;19(1):70.
- **Saldarriaga EM**, Spicknall IH, Pollock ED, Jackson DA, Barbee LA, Bachmann LH, Gift T. *The Reverse Sequence Algorithm is Less Cost-Effective than the Traditional Algorithm at Screening for Syphilis among Gay, Bisexual, and other Men who have Sex with Men*. Submitted Jul 2026
- **Saldarriaga EM**, Vidal E, Burela A, et al. *The Economic Value of Introducing Tafenoquine and G6PD screening for the radical cure of P. vivax Malaria in Peru: A cost-effectiveness and budget impact analysis from the payer's perspective*. Submitted Sept 2026
- **Saldarriaga EM**. *Regional Investment Case for the use of Tafenoquine and G6PD screening for the radical cure of P. vivax malaria in Latin America. Evidence from Peru, Brazil, and Colombia*. Under authors review
- **Saldarriaga EM**, Barnabas R, Zimmermann M, Basu, A. *Cost-Effectiveness Analysis of using localized data to inform resource allocation for HIV services. Case study in Atlanta*. Under authors review
8. **Saldarriaga EM**, Hauber B, Tran J, et al. *Heterogeneity of patient preferences for long-acting HIV treatment among people with HIV in Kenya*. *BMC Infect Dis*. Published online July 10, 2026. doi:10.1186/s12879-026-13927-x
9. Bhardwaj S, Mugisha J, Magembe J, Eram G, Nakyanzi A, Mujugira A, **Saldarriaga EM**, et al. *Men's preferences for HIV self-test distribution strategies in Uganda: A discrete choice experiment*. *J Acquir Immune Defic Syndr*. Published online June 26, 2026. doi:10.1097/QAI.0000000000003922

Preference
Studies

10. Tran J, **Saldarriaga EM**, Kaggiah A, et al. *Patient preferences for long-acting antiretroviral treatment among people with HIV in Kenya: a discrete choice experiment*. BMC Infect Dis. 2026;26(1):570.
11. Maina CN, Kaggiah AW, Barthold D, Tran J, **Saldarriaga EM**, et al. *Adaptation and pilot testing of a discrete choice experiment and survey on patient preferences for long-acting antiretroviral therapies for HIV in Kenya*. AIDS Care. Published online November 22, 2025:1-15.
12. **Saldarriaga EM**, Hauber B, Barthold D, et al. *Patient Preferences for Long-Acting HIV Treatment: A Preference Heterogeneity Assessment*. BMC Infectious Diseases 2025, 25 (1), 237. <https://doi.org/10.1186/s12879-025-10546-w>.
13. **Saldarriaga EM**, Chen Y, Montaña MA, Thuo N, Kiptinness C, Terris-Prestholt F, et al. *Preferences for pre-exposure prophylaxis delivery via online pharmacy among potential users in Kenya: a discrete choice experiment*. J Int AIDS Soc. 2024 Oct;27(10):e26356.
14. Graham SM, Barthold D, Hauber B, Brah AT, **Saldarriaga E**, Collier AC, et al. *U.S. patient preferences for long-acting HIV treatment: a discrete choice experiment*. J Int AIDS Soc. 2023 Jul;26 Suppl 2(Suppl 2):e26099.
15. Chen Y, **Saldarriaga EM**, Montano MA, Ngure K, Thuo N, Kiptinness C, et al. *Assessing preferences for HIV pre-exposure prophylaxis (PrEP) delivery services via online pharmacies in Kenya: protocol for a discrete choice experiment*. BMJ Open. 2023 Apr 3;13(4):e069195.
16. Barthold D, **Saldarriaga EM**, Brah AT, Hauber B, Banerjee P, Fuller SM, et al. *Preference for daily oral pills over long-acting antiretroviral therapy options among people with HIV*. AIDS. 2023 Aug 1;37(10):1545–53.
17. **Saldarriaga EM**, Hauber B, Carlson JJ, Barthold D, Veenstra DL, Devine B. *Assessing Payers' Preferences for Real-World Evidence in the United States: A Discrete Choice Experiment*. Value Health. 2022 Mar;25(3):443–50.

Policy Analysis

18. Williams AM, **Saldarriaga EM**, Cramer R. *State-level trends in access to Medicaid family planning services, 2008-2023*. Health Serv Res. 2024 Oct 22;
19. **Saldarriaga EM**. *An incomplete step in the right direction: Peru's National Institute of Health establishes cost-effectiveness threshold*. Rev Saude Publica. 2023;56:106.
- **Saldarriaga EM**, Williams A, Spicknall I, Pearson B. *The Impact of Medicaid Expansion on the Nationally Notifiable STDs, 2007 – 2022: A Causal Inference Study*. Under institutional clearance.
- Williams A, **Saldarriaga EM**, Miele K, Nguyen A, Eppink S, Romero L, Cramer R. *State Medicaid Family Planning Policies Were Associated with Decreased Rates of Congenital Syphilis*. Under institutional clearance.

Statistical modeling

20. Vasquez-Loarte T, Guerra GA, **Saldarriaga EM**, et al. *Healthcare access satisfaction before and during the COVID-19 pandemic among Peruvian children with down syndrome*. BMC Pediatr. 2025;25(1):874.
21. Montaña MA, Chen Y, **Saldarriaga EM**, et al. *Willingness to pay for HIV pre- and post-exposure prophylaxis services delivered via an online pharmacy in Kenya*. BMC Health Services Research 2025; 25: 576.
22. Clay PA, Pollock ED, **Saldarriaga EM**, et al. *Modeling the Impact of Vaccine Dose Prioritization Strategies During the 2022 Mpox Outbreak*. Am J Epidemiol. Published online March 11, 2025:kwaf054. doi:10.1093/aje/kwaf054

23. **Saldarriaga EM**, Basu A. *Estimation of HIV prevalence at the ZIP code-level in Atlanta, Georgia: Bayesian prediction modeling using passive surveillance data and social determinants of disease spreading*. Public Health. 2024 Oct 28;237:282–90.
24. **Saldarriaga, EM** *Using machine learning to identify COVID-19 vaccine-hesitancy predictors in the USA*. BMJ Public Health 1, 2023 Dec;1(1):e000456. doi:10.1136/bmjph-2023-000456
25. **Saldarriaga EM**. *HIV-Prevalence Mapping Using Small Area Estimation in Kenya, Tanzania, and Mozambique at the First Sub-National Level*. Ann Glob Health. 2021;87(1):93.
26. Miller M, **Saldarriaga EM**, Jones-Smith JC. *Household socioeconomic status modifies the association between neighborhood SES and obesity in a nationally representative sample of first grade children in the United States*. Prev Med Rep. 2020 Dec;20:101207.
27. Bravo-Zúñiga J, **Saldarriaga EM**, Chávez-Gómez R, Gálvez-Inga J, Valdivia-Vega R, Villavicencio-Carranza M, et al. *Effectiveness of adherence to a renal health program in a health network in Peru*. Rev Saude Publica. 2020;54:80.
- **Saldarriaga EM**, Spicknall IH, Clay PA, Romero-Severson E. *Model-Based Estimates of One-Dose and Two-Dose JYNNEOS Vaccine Efficacy Against Mpox Using Surveillance and Vaccine Administration Data Across Counties that had Community Transmission of Mpox*. Under institutional clearance.

Qualitative research

28. Motaze NV, Mthombathi ZE, Adetokunboh O, Hazelbag CM, **Saldarriaga EM**, Mbuagbaw L, et al. *The Impact of Rubella Vaccine Introduction on Rubella Infection and Congenital Rubella Syndrome: A Systematic Review of Mathematical Modelling Studies*. Vaccines (Basel). 2021 Jan 25;9(2).
29. **Saldarriaga EM**, Vodicka E, La Rosa S, Valderrama M, Garcia PJ. *Point-of-Care Testing for Anemia, Diabetes, and Hypertension: A Pharmacy-Based Model in Lima, Peru*. Ann Glob Health. 2017 Apr;83(2):394–404.
30. Siña M, Wood RC, **Saldarriaga E**, Lawler J, Zunt J, Garcia P, et al. *Understanding Perceptions of Climate Change, Priorities, and Decision-Making among Municipalities in Lima, Peru to Better Inform Adaptation and Mitigation Planning*. PLoS One. 2016;11(1):e0147201.

Policy papers

31. Lescano A, Antiporta D, Luna A, **Saldarriaga EM**, et al. *Challenges and Priorities: Peruvian policy in adolescents and youth Lima, PE: The United Nations System in Peru*; 2018 Sep p. 82.

Invited Talks

Saldarriaga EM. *Global Health Equity*. DPE, University of Southern California. Feb 28, 2023.

Saldarriaga EM. *The use of Bayesian prediction models to correct incomplete data, a case of study*. Virtual, Investigation Centre, University of the Pacific, Peru. Nov 15, 2021.

Saldarriaga EM. *The value of reducing uncertainty of HIV-prevalence estimates, at the zip code level. Case of study in Atlanta, Georgia*. Virtual, TH Chan School of Public Health, Harvard. May 21, 2021.

Saldarriaga EM. *Peruvian Health System: Structure and Challenges*. MBA Program, University of Quinnipiac. Lima, Peru. Jun 11, 2017.

Positions

April 2025 – Present

American Dental Education Association (ADEA)

Position	Director of Research & Public Health
Description	Lead the development of ADEA’s research, evaluation, and scientific dissemination function, translating evidence and data into strategic decisions concerning health professions education, innovation adoption, institutional sustainability, and oral-systemic health. - Designed and manage a five-year research and evaluation portfolio aligned with ADEA’s education, advocacy, and innovation priorities, using theories of change and staged outcome measures to assess progress and guide strategic decisions. - Lead program-evaluation research on innovation adoption in oral health education, examining implementation barriers, financial sustainability, clinical readiness, and conditions for institutional scale. - Lead development of a Board-approved, AI-enabled data lake integrating disparate data sources for research and decision-making; oversaw interactive R Shiny dashboards, automated pipelines, evidence-retrieval workflows, and human-review protocols. - Scope, negotiate, contract, and oversee two external partners delivering evidence-synthesis and data-platform capabilities, setting requirements, milestones, validation standards, and review processes. - Translate research and evaluation findings into decision-focused briefs, visualizations, presentations, and tools for association leaders, educational institutions, academic collaborators, and corporate partners.

August 2022 – April 2025

Division of STD Prevention, Centers for Disease Control and Prevention (CDC)

Position	Health Economist, Prevention Effectiveness Fellow
Description	Conducted economic and epidemiological research to generate policy-relevant evidence supporting the design, adoption, and scale-up of national and local STD prevention and control strategies. Led economic evaluations to assess the cost-effectiveness of interventions and optimize resource allocation and conducted policy analyses on the impacts of the Affordable Care Act and family planning policies on STI outcomes. <i>Key Accomplishments:</i> - Research Leadership: Collaborated with academic and government partners on nine research projects, serving as principal investigator on three. - Policy Impact: Produced economic and policy analyses that informed federal and local decision-making on STD prevention strategies and healthcare coverage. - Scientific Contribution: Published two peer-reviewed articles, with five additional manuscripts under review or co-author development. - Collaboration: Partnered extensively with multidisciplinary teams across federal agencies, public health departments, and academia. - Knowledge Translation: Disseminated findings through three national scientific conferences, Division-wide briefings, and multiple methodological presentations.

	September 2017 – June 2022 The CHOICE Institute and Department of Health Services, University of Washington
Position	Research Associate
Description	I held Research Assistant positions with The CHOICE Institute, the School of Pharmacy, the School of Global Health, and the School of Public Health. My research focused on the efficiency of resource allocation for health interventions, health technology assessment for medical and non-medical innovations in healthcare, and treatment preference elicitation to inform decision-making for payers and patients. <i>Key Accomplishments:</i> - In addition to my formal training in econometrics and decision sciences, I independently developed advanced expertise in spatial statistics, Bayesian statistics, infectious and chronic disease modeling, and preference elicitation methods. - Published 17 papers in peer-reviewed journals, with 9 as first author. - Collaborated on each project with multidisciplinary teams, often including economists, epidemiologists, medical professionals, and mathematicians. - Contributed to the development of research grant proposals and successfully secured two school-wide student research funding awards. Received a school-wide Outstanding Dissertation Award and a university-wide award for my ability to effectively communicate research findings to broad audiences.
	April 2017 – August 2017 Ministry of Health
Position	Analyst, Vice-ministry of Healthcare and Insurance
Description	Led the design and implementation of a national intelligence unit to monitor coverage of key childhood and prenatal health interventions across all publicly funded facilities. Strengthened drug inventory management, demand forecasting, and access to essential medicines with the aim of preventing resource shortages and improving service delivery equity. <i>Key Accomplishments:</i> - System Strengthening: Developed national metrics to monitor drug inventories for childhood respiratory and gastrointestinal treatments, vaccinations, and prenatal screenings. - Policy Consensus: Achieved cross-stakeholder agreement on indicators with the Ministry of Health and national health institutes, ensuring institutional adoption. - Forecasting & Analytics: Built statistical models to forecast service demand and anticipate supply shortages up to two months in advance, enabling proactive interventions.

July 2014 – March 2017

School of Public Health, University Cayetano Heredia

Position Researcher

Description I conducted economic evaluations of novel technologies for screening sexually transmitted and chronic diseases, as well as public policy analysis.

Key Accomplishments:

- Contributed to nine research projects, serving as the lead investigator for two: an economic analysis of HPV disease burden and an evaluation of point-of-care testing for chronic diseases.
- Built significant collaborations with the School of Public Health (laboratory and epidemiology departments), Peru's Ministries of Development and Finance, pharmaceutical companies, and the United Nations System.
- Published two peer-reviewed journal articles and authored one policy report.

Teaching

Jun 2020 – Jun 2022 The CHOICE Institute, University of Washington. Teaching Assistant in the Certificate in Health Economics and Outcomes Research.

Jul 2015 – Jul 2016 School of Public Health and Administration, University Cayetano Heredia, PE. Lecturer in Economics.

Mar 2010 – Jul 2014 Department of Economics, School of Economics. University of the Pacific, PE. TA in Macroeconomics, Introduction to Economics, and Econometrics.

Service

2025 - BMC Health Services Research, Editorial Board Member

2020 - Reviewer for scientific journals: Journal of Biomedical Informatics, Value in Health, Journal of Infectious Diseases, Journal of the International AIDS Society.

2023 Co-Chair Global Health Interest Group, Society of Medical Decision Making.

2020-2022 Abstracts Reviewer for the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) annual conferences.

2020 – 2022 Representative in the School of Pharmacy Diversity, Equity, and Inclusion Council (DEIC). Chair of the Recruitment, Retention, and Development Working group.

2020 Student representative in the CHOICE Institute PhD Admission Committee

2019 – 2020 President of the University of Washington's Student Chapter of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Consulting

2025 Consultant, CueZen. Modeled population-level health outcomes of a mobile-delivered behavioral nudge intervention targeting physical activity and food purchasing,

2023 – 2025 Consultant, Medicines for Malaria Venture, Switzerland. Cost-effectiveness and budget impact analyses for treating malaria *P. vivax* with tafenoquine in the Peru.

2022 – 2025 Consultant, University of Washington, School of Global Health, U.S.. Statistical analysis for the preference elicitation of long-acting antiretroviral therapy among people with HIV in the U.S. and Kenya.

2021-2022 Co-consultant, Foundation Medicine. Developing a discrete choice experiment to assess provider's preferences for precision medicine tools for the treatment of lung cancer.

2018 – 2019 Consultant, Peruvian Institute for Health Technology Assessment, Peru. Costs-effectiveness analysis of an intervention to prevent chronic kidney diseases.

2016 – 2017 Co-consultant, Merck, Peru. Investment case for Nona valent HVP Vaccine: Costing evaluation of genital warts in Peru.

2015 Research assistant, Ministry of Economics and Finance, Peru. Impact assessment of a conditional cash transfer program on key educational and health metrics of early child development.

Focused Training

July 2024 **16th Summer Institute in Statistics and Modeling in Infectious Diseases (SISMID).** Emory University, Atlanta, GA, USA.

Jun – Aug 2021 **Internship in Value and Access Strategy.** Xcenda, TX, USA

Jun 2021 **Global School on Empirical Research Methods (GSERM) – Bayesian Data Analysis.** St. Gallen University, Switzerland

Jul 2020 **12th Summer Institute in Statistics and Modeling in Infectious Diseases (SISMID).** University of Washington, Seattle, WA, USA

Aug – Nov 2019 **Internship in Health Economics.** Institute for Disease Modeling (IDM), Intellectual Ventures. Bellevue, WA, USA

May – Jun 2019 **Clinic on Meaningful Modeling of Epidemiological Data (MMED).** African Institute for Mathematical Sciences. Cape Town, South Africa

Jul 2014 – Jun 2015 **KUSKAYA: An Interdisciplinary Training Program for Innovation in Global Health.** Fogarty International Center, NIH. Lima, Peru

Jul – Aug 2016 **Summer School in Development Policy.** University of Bonn. Bonn, Germany

Skills

Core competencies

- Decision Science, Cost-effectiveness, and Health Economics
- Strategic Leadership & Policy Development
- Market Access
- Health Technology Assessment (HTA)
- Resource Mobilization & Partnerships
- Team Leadership
- Scientific communication. Tailor scientific messaging to the target audience

Technical skills

- Coding Languages: R, Stata, Stan.
- Decision science: Probabilistic decision modeling, economic evaluation, preferences elicitation, uncertainty assessment, disease modeling.
- Statistics and econometrics: Generalized linear models & methods for causal inference; system of equations; Bayesian regression; Spatial analysis of epidemiological data; machine learning.
- Data Visualization: Use of data visualization and storytelling to better communicate complex information.